Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Preferred Stock Liabilities (2023 - 2024)

Zenas BioPharma (ZBIO) has 2 years of Preferred Stock Liabilities data on record, last reported at $956000.0 in Q2 2024.

  • For Q2 2024, Preferred Stock Liabilities changed N/A year-over-year to $956000.0; the TTM value through Jun 2024 reached $956000.0, changed N/A, while the annual FY2023 figure was $250.1 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $956000.0 in Q2 2024 per ZBIO's latest filing, down from $193.3 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $250.1 million in Q4 2023 and bottomed at $956000.0 in Q2 2024.